Browse by author
Lookup NU author(s): Professor Stephen Proctor, Dr Jennifer Wilkinson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In Hodgkin's lymphoma therapy, there remain areas of extreme difficulty. This article briefly explores these areas and provides evidence that risk-related therapy and web-based data collection programmes can facilitate progress. Unpublished data from the northern region of the UK suggest that risk-based therapy among poor-prognosis Hodgkin's lymphoma patients aged 15-19 years is improving outcome. An index developed at the Memorial Sloan-Kettering Cancer Centre (MSKCC) for patients undergoing salvage therapy shows that new second-line regimens are urgently needed for those with poor prognosis. In primary therapy and relapse, both adolescent and adult patients with Hodgkin's lymphoma should receive treatment tailored to their degree of risk. Elderly patients with Hodgkin's lymphoma are also difficult to treat and fewer than 2% enter randomised clinical trials. We require new means of encouraging international pooling of data and treatment evaluation in such patients. The SHIELD project (Study of Hodgkin's lymphoma in the Elderly Lymphoma Database; www.shieldstudy.co.uk) is now successfully providing on-line registration in the ongoing phase II study of VEPEMB (vinblastine, cyclophosphamide, procarbazine, prednisolone, mitoxantrone and bleomycin) in the elderly and guidance on obtaining ethical approval for participation. © 2006 Oxford University Press.
Author(s): Proctor SJ, Wilkinson J
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: 9th International Conference on Malignant Lymphoma
Year of Conference: 2006
Pages: iv15-iv17
ISSN: 0923-7534
Publisher: Annals of Oncology, Oxford University Press
URL: http://dx.doi.org/10.1093/annonc/mdj993
DOI: 10.1093/annonc/mdj993
PubMed id: 16702179
Library holdings: Search Newcastle University Library for this item
Sponsor(s): Baxter Oncology GmbH
ISBN: 15698041
